Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yoo, Byong C ^a   Kong, Sun Young ^b   Jang, Sang Geun ^a   Kim, Kyung Hee ^a   Ahn, Sun A ^a   Park, Weon Seo ^b   Park, Sohee ^a   Yun, Tak ^a   Eom, Hyeon Seok ^a,b  

^a National Cancer Center   (South Korea)

^b Division of Translational and Clinical Research II   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; LOW MASS ION PROFILING; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; NONHODGKIN LYMPHOMA; NONHUMAN; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDITY; AGED; CASE CONTROL STUDY; CLINICAL CHEMISTRY; MALE; METABOLOMICS; METHODOLOGY; MIDDLE AGED; URINE;

AGED; CASE-CONTROL STUDIES; CHEMISTRY, CLINICAL; FEMALE; HUMANS; HYPOXANTHINE; LYMPHOMA, NON-HODGKIN; MALE; METABOLOMICS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77649331134     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-55     Document Type: Article

References (15)

1. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl 12):1-39. 10.1002/ijc.22719, 17405121.
2. Morrison VA. Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma. Oncology (Williston Park) 2007, 21:1104-1110.
3. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006, 7(Suppl 1):S7-13. 10.3816/CLM.2006.s.002, 17101073.
4. Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P, Pectasides D, Karabelis A, Giannakakis T, Symeonidis A, Papadopoulos A, Antoniou F, Pavlidis N. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998, 55:405-415. 10.1159/000011886, 9732217.
5. Ozgüroglu M, Turna H, Demir G, Döventas A, Demirelli F, Mandel NM, Büyükünal E, Serdengeçti S, Berkarda B. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma. Am J Clin Oncol 1999, 22:615-618. 10.1097/00000421-199912000-00014, 10597748.
6. Mihaljević B, Nedeljkov-Janćić R, Cemerikić-Martinović V, Babić D, Colović M. Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma. Med Oncol 2006, 23:83-89. 10.1385/MO:23:1:83, 16645233.
7. Lee HL, Eom HS, Yun T, Kim HJ, Park WS, Nam BH, Moon-Woo S, Lee DH, Kong SY. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma. Cytokine 2008, 43:71-75. 10.1016/j.cyto.2008.04.004, 18502145.
8. Vannoni D, Porcelli B, Caldarone R, Garzi A. Purine metabolism in human tumors. Medicina (Firenze) 1989, 9:51-54.
9. Hashimoto H, Kubota M, Shimizu T, Kasai Y, Sano H, Adachi S, Akiyama Y, Mikawa H. Effect of high-dose methotrexate on plasma hypoxanthine and uridine levels in patients with acute leukemia or non-Hodgkin lymphoma in childhood. Leukemia 1992, 6:1199-1202.
10. Harkness RA. Hypoxanthine, xanthine and uridine in body fluids, indicators of ATP depletion. J Chromatogr 1988, 429:255-278. 10.1016/S0378-4347(00)83873-6, 3062020.
11. Obajimi O, Melera PW. The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells. Cancer Chemother Pharmacol 2008, 62:215-226. 10.1007/s00280-007-0593-6, 17896107.
12. Buhl L, Dragsholt C, Svendsen P, Hage E, Buhl MR. Urinary hypoxanthine and pseudouridine as indicators of tumor development in mesothelioma-transplanted nude mice. Cancer Res 1985, 45(3):1159-1162.
13. Linder N, Martelin E, Lundin M, Louhimo J, Nordling S, Haglund C, Lundin J. Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. Eur J Cancer 2009, 45:648-655. 10.1016/j.ejca.2008.10.036, 19112016.
14. Fini MA, Orchard-Webb D, Kosmider B, Amon JD, Kelland R, Shibao G, Wright RM. Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase. J Cell Biochem 2008, 105:1008-1026. 10.1002/jcb.21901, 2587521, 18767115.
15. Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res 2005, 11:4372-4381. 10.1158/1078-0432.CCR-04-2280, 15958620.